ACGIH: TWA 0.5 ppm; STEL 1 ppmNIOSH: TWA 5 ppm(30 mg/m3)
LogP:
3.300 (est)
物理描述:
Dicyclopentadiene appears as a liquid with an acrid odor. Flash point 90°F. The vapors are irritating to the eyes and respiratory system. Subject to polymerization if subjected to heat for prolonged periods or if contaminated. If the polymerization takes place inside a container, the container may violently rupture. Insoluble in water. Density 8.2 lb / gal. Used in paints, varnishes, as an intermediate in insecticides, as a flame retardant in plastics.
颜色/状态:
Colorless crystalline solid [Note: A liquid above 90 degrees F]
气味:
Disagreeable camphor-like odor
蒸汽密度:
4.55 (NTP, 1992) (Relative to Air)
蒸汽压力:
2.30 mm Hg at 25 °C /Extrapolated from a measured range of 33 °C and higher/
亨利常数:
Henry's Law constant = 0.02 atm-cum/mol at 25 °C (est)
When given by oral admin to lactating cows, metabolites were present in urine mainly in form of glucuronide conjugates. It is suggested that epoxidation of double bonds occurred, followed by hydrolysis of epoxides to diols & conjugation with glucuronic acid.
... Urinary metabolites of dicyclopentadiene were not identified specifically, but analysis by thin layer chromatography indicated that the urine of mice and rats each had seven components. Six components were found in the urine of dogs. The Rf values of these components were similar; therefore, common metabolites were indicated in all three species. Only 1-3% of the radioactivity was attributed to nonmetabolized (14)carbon-dicyclopentadiene in all three species. When the urine from all species was subjected to enzymatic hydrolysis by glusulase (beta glucuronidase and sulfatase) and extracted, was recovered in the extract, indicating the presence of urine conjugates.
IDENTIFICATION AND USE: Dicyclopentadiene (DCPD) is a colorless crystalline solid (a liquid above 90 degrees F). DCPD is used in the manufacture of cyclopentadiene as a pesticide intermediate; in the production of ferrocene compounds; in paints, varnishes, and resin manufacture; in production of elastomers, resin systems, and polymers. It is also used as a repellent for animals such as hares, rabbits, and deer, in winter or in summer. Applied in the form of impregnated strip on deciduous and coniferous trees, or by spraying around ornamental plants and shrubs. HUMAN EXPOSURE AND TOXICITY: Signs of exposure after inhalation--cough, sore throat, and headache; skin exposure--redness and pain; eyes exposure--redness and pain; Ingestion--abdominal pain, and nausea. Human sensory responses to DCPD were studied in three human volunteers. The odor threshold was reported to be as low as 0.003 ppm. In two of the subjects exposed to 1 and 5.5 ppm for 30 minutes, one subject experienced mild eye and throat irritation after 7 minutes at 1 ppm, and the other subject reported olfactory fatigue after 24 minutes. Eye irritation was reported after 10 minutes, but no olfactory fatigue was reported by either test subject at 5.5 ppm. Accidental exposures of workers, in which headaches were experienced during first 2 months but were not experienced during next 3 months, indicate a certain degree of inurement. ANIMAL STUDIES: In rabbits it was slightly irritating to skin and eyes. Three of four rats survived ten 6-hour daily exposures at 250 ppm, and all survived 15 such exposures at 100 ppm. On daily, repeated exposures to DCPD for 10 days, rats succumbed at the 332 ppm level, but not at the 146 and 72 ppm levels. All dying rats succumbed with convulsions and hemorrhage of the lungs with blood in the intestines; with the females, hemorrhage of the thymus. Mice exposed under the same schedule died at both 146 and 72 ppm. After exposures of 7 hours/day for 89 exposure days, kidney damage was seen in rats exposed at 74 and 35 ppm DCPD. Some lung involvement was seen as chronic pneumonia and bronchiectasis, but no dose related effect was seen in other organs examined. Dogs exposed under the same schedule (89 exposure days) at 32, 23, and 9 ppm DCPD showed only minimal changes in the biochemical tests used, and no changes that were dose-related in 28 organs examined. Hyaline droplets in the proximal convoluted tubular epithelial cells of the kidney were seen in male rats exposed to 5 and 50ppm DCPD and tubular proteinosis was seen by week 13 in all male rats exposed to 50ppm DCPD. Mice were exposed to DCPD by inhalation for 7 hours per day, 5 days per week for 10 days at 47, 72, and 146 ppm. All mice exhibited convulsive deaths on the first day of exposure. Death at 72 ppm occurred in five of six mice of each sex during the 10 days of exposure and was not associated with the convulsions or gross lesions observed in rats. No deaths occurred at 47 ppm and no other effects of treatment were observed. In other study four groups, each consisting of 45 male and 45 female B6C3F1 mice, were exposed to DCPD vapor by inhalation 6 hr/day, 5 days/week, for 13 weeks (64 exposures) at targeted concentrations of 0, 1.0, 5.0, or 50 ppm. Ten male and nine female mice in the highest exposure group died during the study, while no more than two mice died in any other group. 20 female pregnant rats were admin DCPD orally at 0, 80, 250, 750 mg/kg/day for days 6 to 15 gestation. On day 19, the dams were sacrificed and examined; each uterus was examined for implantation sites, placement in uterine horns, number of live and dead fetuses and resorptions. Fetuses were examined for soft tissue changes and skeletal abnormalities. No compound-related gross pathological effects or changes in reproductive performance were seen in the dams. There were no visceral or skeletal malformations or changes in sex ratio in the fetuses. DCPD was not mutagenic in the Salmonella assay at doses of 0, 3, 10, 33, 100, and 333 ug/plate in Salmonella typhimurium strains (TA98, TA100, TA1535, and TA1537) with or without metabolic activation. DCPD did not induce structural chromosomal aberration or polyploidy in CHL/IU cells; negative finding were confirmed in the in vitro micronucleus test.
来源:Hazardous Substances Data Bank (HSDB)
毒理性
暴露途径
该物质可以通过吸入和摄入被身体吸收。
The substance can be absorbed into the body by inhalation and by ingestion.
来源:ILO-WHO International Chemical Safety Cards (ICSCs)
毒理性
暴露途径
吸入,吞食,皮肤和/或眼睛接触
inhalation, ingestion, skin and/or eye contact
来源:The National Institute for Occupational Safety and Health (NIOSH)
In general, although some dicyclopentadiene can be exhaled unchanged, most of that absorbed is hydroxylated in the liver, undergoes glucuronide conjugation, and is excreted in the urine.
/MILK/ When given by oral administration to lactating cows urine and feces contained 86% of administered dose with only trace amounts being secreted in milk. Some may have been eliminated in gaseous form. Compound was extensively absorbed from GI tract.
来源:Hazardous Substances Data Bank (HSDB)
吸收、分配和排泄
二环戊二烯被预测为无论通过任何给药途径都会被迅速吸收和分布。它从胃肠道被广泛吸收。
Dicyclopentadiene is predicted to be rapidly absorbed and distributed following any route of administration. It is extensively absorbed from the GI tract.
来源:Hazardous Substances Data Bank (HSDB)
吸收、分配和排泄
该物质可以通过吸入和摄入被身体吸收。
The substance can be absorbed into the body by inhalation and by ingestion.
Tetramethylenephosphonate derivatives of norborane (TPNB) and dicyclopentadiene (TPDCPD) were shown to readily form stable chelates with (99m)Tc that had high and selective bone uptake. The skeletal uptake and blood clearance properties of (99m)Tc-TPNB were similar to (99m)Tc-MDP in both rats and rabbits. This suggests additional studies to further evaluate (99m)Tc-TPNB or perhaps other large-organic based multidentate phosphonate ligands as potential bone imaging agents is warranted.
1.周国泰,化学危险品安全技术全书,化学工业出版社,1997 2.国家环保局有毒化学品管理办公室、北京化工研究院合编,化学品毒性法规环境数据手册,中国环境科学出版社.1992 3.Canadian Centre for Occupational Health and Safety,CHEMINFO Database.1998 4.Canadian Centre for Occupational Health and Safety, RTECS Database, 1989
Chiral Anion Phase-Transfer Catalysis Applied to the Direct Enantioselective Fluorinative Dearomatization of Phenols
作者:Robert J. Phipps、F. Dean Toste
DOI:10.1021/ja311798q
日期:2013.1.30
ambient reaction conditions with high enantioselectivity. The close relationship of the products with well-studied o-quinols provides numerous avenues for syntheticelaboration and exciting opportunities for bioisosteric replacement of hydroxyl with fluorine in natural products.
Compounds of the formula
1
where
R
1
is of the formulae
2
R
2
is —R
4
, —O—R
4
, —O—S (O)
2
—R
4
, —NR
4
R
5
, R
4
—(CH
2
)
b
—NH(C═X)—(CH
2
)—, R
4
—(CH
2
)
b
—O(C═O)NH—(CH
2
)
c
—(C═O)NH—, R
4
(C═O)NH—(C═O)NH—, —(CH
2
)
b
—NH(C═X)—(CH
2
)
c
—R
4
, R
4
—(CH
2
)
b
—O(C═)—(CH
2
)
c
—, —(CH
2
)
b
—O(C═O)—(CH
2
)
c
—R
4
, —NH(C═X)NH—R
4
, R
4
—O(C═O)O—, —O(C═)NH—R
4
, R
4
—O(C═O)NH—, —(CH
2
)
b
—(C═0)—(CH
2
)
c
—R
4
, —NH—S(O)
2
—R
4
, —C(OH)R
4
R
5
, —CH(OH)—R
4
, —(C═O)—NR
4
R
5
, —CN, —NO
2
, substituted C
1
to C
6
alkyl, substituted or unsubstituted C
1
to C
6
alkenyl, or substituted or unsubstituted C
1
to C
6
alkynyl, said substituted moieties substituted with a moiety of the formulae —R
4
, —R
4
R
5
, —O—R
4
, or —S(O)
d
—R
4
. These compounds are useful psychotherapeutics and are potent serotonin (5-HT
1
) agonists and antagonists and may be used in the treatment of depression, anxiety, eating disorders, obesity, drug abuse, cluster headache, migraine, pain and chronic paroxysmal hemicrania and headache associated with vascular disorders, and other disorders arising from deficient serotonergic neurotranmission. The compounds can also be used as centrally acting antihypertensives and vasodilators.
Compositions containing sertraline and a 5-HT.sub.1D receptor agonist or
申请人:Pfizer Inc.
公开号:US05597826A1
公开(公告)日:1997-01-28
The present invention relates to novel compositions containing the serotonin selective re-uptake inhibitor (SSRI), preferably (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenam ine, and an agonist or antagonist of the serotonin 1 (5-HT.sub.1) receptor and to the use of such compositions for treating or preventing a condition selected from mood disorders, including depression, seasonal affective disorders and dysthmia, anxiety disorders including generalized anxiety disorder and panic disorder; agoraphobia, avoidant personality disorder; social phobia; obsessive compulsive disorder; post-traumatic stress disorder; memory disorders including dementia, amnestic disorders and age-associated memory impairment; disorders of eating behavior, including anorexia nervosa and bulimia nervosa; obesity; cluster headache; migraine; pain; Alzheimer's disease; chronic paroxysmal hemicrania; headache associated with vascular disorders; Parkinson's disease, including dementia in Parkinson's disease, neuroleptic-induced parkinsonism and tardive dyskinesias; endocrine disorders such as hyperprolactinaemia; vasospasm (particularly in the cerebral vasculature); hypertension; disorders in the gastrointestinal tract where changes in motility and secretion are involved; sexual dysfunction, including premature ejaculation; and chemical dependencies.
Addition of C–H Bonds of Pyridine Derivatives to Alkenes Catalyzed by Zirconium Complexes Bearing Amine-Bridged Bis(phenolato) Ligands
作者:Qiu Sun、Ping Chen、Yaorong Wang、Yunjie Luo、Dan Yuan、Yingming Yao
DOI:10.1021/acs.inorgchem.8b01959
日期:2018.9.17
Cationic zirconium complexes in situ generated from zirconium dibenzyl complexes bearing amine-bridged bis(phenolato) ligands have been developed to catalyze addition of C(sp2)–H and C(sp3)–H bonds of pyridine derivatives to alkenes. A series of zirconium complexes bearing different ligands have been synthesized, and their activities in catalyzing addition of C(sp3)–H bonds of pyridine derivatives to alkenes